CymaBay Therapeutics(CBAY) - 2023 Q1 - Quarterly Report

Total project costs decreased $2.3 million to $9.3 million from $11.6 million for the three months ended March 31, 2023 and 2022, respectively. The decrease was mostly due to the completion of enrollment of our RESPONSE trial and lower spending in drug manufacturing and development for PBC during the three months ended March 31, 2023. Project costs for the three months ended March 31, 2023 and 2022 primarily consisted of seladelpar-related clinical trial expenses for PBC. Internal research and development c ...